Tracon Pharmaceuticals, Inc. (Tracon), a clinical-stage biopharmaceutical company, has announced the offering of common stock with aggregate sales proceeds of up to $6,151,388 through a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. The offering is being made through JonesTrading Institutional Services LLC (JonesTrading), acting as sales agent or principal. This offering is part of a previously established Capital on DemandTM Sales Agreement with JonesTrading, dated December 9, 2020, and amended on March 15, 2022. Tracon has previously sold $10.2 million worth of shares under this agreement. The common stock is traded on the Nasdaq Capital Market under the symbol 'TCON.' As of April 11, 2024, the last reported sales price was $2.59 per share. The public float was approximately $32.4 million, based on the...Show More

Tracon Pharmaceuticals, Inc. (Tracon), a clinical-stage biopharmaceutical company, has announced the offering of common stock with aggregate sales proceeds of up to $6,151,388 through a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. The offering is being made through JonesTrading Institutional Services LLC (JonesTrading), acting as sales agent or principal. This offering is part of a previously established Capital on DemandTM Sales Agreement with JonesTrading, dated December 9, 2020, and amended on March 15, 2022. Tracon has previously sold $10.2 million worth of shares under this agreement. The common stock is traded on the Nasdaq Capital Market under the symbol 'TCON.' As of April 11, 2024, the last reported sales price was $2.59 per share. The public float was approximately $32.4 million, based on the shares held by non-affiliates and the last reported sale price on March 13, 2024. The company has sold approximately $4.6 million of securities in the past 12 months under the General Instruction I.B.6 of Form S-3. The current prospectus supplement relates to the offer and sale of additional shares with an aggregate offering price of up to $6,151,388. The sales may be made in 'at the market offerings' as defined in Rule 415 under the Securities Act. JonesTrading will receive a commission of 2.5% of the gross proceeds from any sales made under the Sales Agreement. The date of the prospectus supplement is April 12, 2024.